Product Description: Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Amitkumar Mehta, et al. Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results. Blood (2021) 138 (Supplement 1): 3542.